 InPharm | Big pharma: big rewards come from big risks InPharm This effort produced tofacitinib, a very exciting, first-in-class small molecule to treat rheumatoid arthritis, psoriasis and may prove to be valuable in preventing organ transplant rejection. I believe Pfizer plans to submit the NDA for this shortly. ... |
